Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson’s disease (PD) and LRRK2 kinase inhibitors are currently being tested in early phase clinical trials. In order to ensure the highest chance of success, a biomarker-guided entry into clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Hunt, C. P., Thacker, E. A., Toste, C. M., Boularand, S., Deprets, S., Dubois, L., Sanders, L. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557909/
https://www.ncbi.nlm.nih.gov/pubmed/33057100
http://dx.doi.org/10.1038/s41598-020-74195-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557909/
https://www.ncbi.nlm.nih.gov/pubmed/33057100
http://dx.doi.org/10.1038/s41598-020-74195-6

Ejemplares similares